Invitrogen™ CD272 (BTLA) Monoclonal Antibody (MIH26), eBioscience™

Description

Description: The BTLA monoclonal antibody reacts with human B and T lymphocyte attenuator (BTLA). BTLA is expressed by peripheral lymphocytes, splenic macrophages, developing B cells in the bone marrow and developing T cells in the thymus and mature, but not immature bone marrow-derived dendritic cells. BTLA is implicated as a negative regulator of the activation and/or function of various hemopoietic cell types. It is reported that BTLA binds to B7-H4, but further studies are needed to confirm this interaction. Applications Reported: This MIH26 antibody has been reported for use in flow cytometric analysis. Applications Tested: This MIH26 antibody has been tested by flow cytometric analysis of nomral human peripheral blood. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

BTLA or B and T-lymphocyte attenuator is a member of the co-inhibitory receptors of the CD28 superfamily. BTLA is a lymphocyte inhibitory receptor which inhibits lymphocytes during immunes responses. BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation. It remains expressed on Th1 cells, but not Th2 cells. BTLA is a unique co-receptor that interacts with the tumor necrosis factor receptor superfamily member herpesvirus entry mediator (HVEM). This interation is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response.